Industry-Standard Drug Discovery
Turning scientific concepts into drug candidates is a challenge that our scientists meet every day. With 30 years of drug discovery research carried-out at our premises, over a hundred projects delivering proofs of principle, lead molecules and optimized leads / preclinical drug candidates have been managed by Metabrain staff. This experience acquired in the industry is invaluable in the context of a PRO helping biotech, pharma and the food industries add-value to their product portfolio and develop innovative products.
Our experience in drug discovery and expertise acquired in the industry truly puts us in a position to design programs, manage collaborative projects and be an outstanding contributor to pharma, biotech & food industries.
Proof of Principle
Multifactorial diseases such as diabetes or Alzheimer’s disease remain poorly understood and this complicates the discovery of innovative drugs. Metabrain has a wide range of molecular and cellular biology capacities that combine with in vivo models mimicking the naturally occurring forms of diseases. Furthermore, we entertain strong links with academia and coordinate research projects taking advantage of world-class expertise, not only to discover novel target, but also to contribute to better understand the disease we strive to treat and prevent. We believe connecting in such fashion applied and basic researchers is a critical aspect of breakthrough research.
Hit to Lead to Preclinical Candidate
Metabrain’s “hit-to-candidate” activities benefits from the stringent standards of the industry, that ensure chemical synthesis procedures and screening cascades provide reproducible results year after year. Such programs are rigorously designed and planned and we take great care in analyzing each data generated that could potentially affect the planned schedule, should it lead to going further that what was originally planned.
Product valorization
Our experience in the pharmaceutical industry puts us in an ideal position to help biotech and start-up companies develop their products in the best possible ways. By anticipating the expectation of patients, the market, pharmaceutical business development teams and investors, we provide concrete help to our partners make the right decisions.
Indeed, the drugs that are needed at the moment and in the future do not solely need to have an innovative, differential mechanisms of action, solid proofs of concepts and proofs of principle, but also a “proof of relevance”… Indeed, it is critical that the drugs discovered today stand a chance to be accepted by the doctors and national insurances in particular tomorrow. Collaborating with Metabrain is therefore more than a scientific and human experience, indeed the marketing and regulatory aspects of the products developed are also integrated into our vision of successful drug candidates.